CIPHER PHARMACEUTICALS INC (CPH.CA) Fundamental Analysis & Valuation

TSX:CPH • CA17253X1050

15.16 CAD
+0.43 (+2.92%)
Last: Mar 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CPH.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

Overall CPH gets a fundamental rating of 7 out of 10. We evaluated CPH against 34 industry peers in the Pharmaceuticals industry. CPH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CPH is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make CPH a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

8

1. CPH.CA Profitability Analysis

1.1 Basic Checks

  • CPH had positive earnings in the past year.
  • CPH had a positive operating cash flow in the past year.
  • In the past 5 years CPH has always been profitable.
  • In the past 5 years CPH always reported a positive cash flow from operatings.
CPH.CA Yearly Net Income VS EBIT VS OCF VS FCFCPH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 11.77%, CPH belongs to the top of the industry, outperforming 91.18% of the companies in the same industry.
  • The Return On Equity of CPH (15.23%) is better than 88.24% of its industry peers.
  • The Return On Invested Capital of CPH (7.23%) is better than 88.24% of its industry peers.
  • CPH had an Average Return On Invested Capital over the past 3 years of 8.42%. This is in line with the industry average of 8.22%.
Industry RankSector Rank
ROA 11.77%
ROE 15.23%
ROIC 7.23%
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
CPH.CA Yearly ROA, ROE, ROICCPH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

  • With an excellent Profit Margin value of 34.68%, CPH belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • CPH's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 25.51%, CPH belongs to the best of the industry, outperforming 85.29% of the companies in the same industry.
  • CPH's Operating Margin has declined in the last couple of years.
  • The Gross Margin of CPH (74.32%) is better than 94.12% of its industry peers.
  • CPH's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 25.51%
PM (TTM) 34.68%
GM 74.32%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
CPH.CA Yearly Profit, Operating, Gross MarginsCPH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CPH.CA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CPH is destroying value.
  • The number of shares outstanding for CPH has been increased compared to 1 year ago.
  • The number of shares outstanding for CPH has been reduced compared to 5 years ago.
  • The debt/assets ratio for CPH is higher compared to a year ago.
CPH.CA Yearly Shares OutstandingCPH.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CPH.CA Yearly Total Debt VS Total AssetsCPH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 6.53 indicates that CPH is not in any danger for bankruptcy at the moment.
  • CPH has a better Altman-Z score (6.53) than 94.12% of its industry peers.
  • The Debt to FCF ratio of CPH is 0.45, which is an excellent value as it means it would take CPH, only 0.45 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 0.45, CPH belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
  • A Debt/Equity ratio of 0.12 indicates that CPH is not too dependend on debt financing.
  • CPH has a Debt to Equity ratio of 0.12. This is in the better half of the industry: CPH outperforms 70.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.45
Altman-Z 6.53
ROIC/WACC0.85
WACC8.56%
CPH.CA Yearly LT Debt VS Equity VS FCFCPH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.30 indicates that CPH should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.30, CPH is doing worse than 67.65% of the companies in the same industry.
  • CPH has a Quick Ratio of 1.30. This is a bad value and indicates that CPH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.98, CPH is in line with its industry, outperforming 41.18% of the companies in the same industry.
  • The current and quick ratio evaluation for CPH is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.98
CPH.CA Yearly Current Assets VS Current LiabilitesCPH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. CPH.CA Growth Analysis

3.1 Past

  • CPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.76%.
  • CPH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.97% yearly.
  • Looking at the last year, CPH shows a very strong growth in Revenue. The Revenue has grown by 89.17%.
  • Measured over the past years, CPH shows a quite strong growth in Revenue. The Revenue has been growing by 8.25% on average per year.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%

3.2 Future

  • The Earnings Per Share is expected to grow by 20.66% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, CPH will show a very strong growth in Revenue. The Revenue will grow by 27.91% on average per year.
EPS Next Y52.6%
EPS Next 2Y14.3%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue Next Year51.28%
Revenue Next 2Y24.88%
Revenue Next 3Y27.91%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CPH.CA Yearly Revenue VS EstimatesCPH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
CPH.CA Yearly EPS VS EstimatesCPH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

6

4. CPH.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 16.84, CPH is valued correctly.
  • 82.35% of the companies in the same industry are more expensive than CPH, based on the Price/Earnings ratio.
  • CPH's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.29.
  • Based on the Price/Forward Earnings ratio of 18.48, the valuation of CPH can be described as rather expensive.
  • Based on the Price/Forward Earnings ratio, CPH is valued a bit cheaper than the industry average as 70.59% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.60, CPH is valued a bit cheaper.
Industry RankSector Rank
PE 16.84
Fwd PE 18.48
CPH.CA Price Earnings VS Forward Price EarningsCPH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPH is on the same level as its industry peers.
  • Based on the Price/Free Cash Flow ratio, CPH is valued a bit cheaper than the industry average as 76.47% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.38
EV/EBITDA 14.5
CPH.CA Per share dataCPH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CPH has an outstanding profitability rating, which may justify a higher PE ratio.
  • CPH's earnings are expected to grow with 20.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.32
PEG (5Y)1.3
EPS Next 2Y14.3%
EPS Next 3Y20.66%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CPH.CA Dividend Analysis

5.1 Amount

  • CPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CPH.CA Fundamentals: All Metrics, Ratios and Statistics

CIPHER PHARMACEUTICALS INC

TSX:CPH (3/6/2026, 7:00:00 PM)

15.16

+0.43 (+2.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners1.32%
Inst Owner ChangeN/A
Ins Owners3.63%
Ins Owner ChangeN/A
Market Cap383.24M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts77.5
Price Target19.58 (29.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)0%
PT rev (3m)6.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.79%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)0.21%
Valuation
Industry RankSector Rank
PE 16.84
Fwd PE 18.48
P/S 5.61
P/FCF 9.38
P/OCF 9.36
P/B 2.46
P/tB 12.29
EV/EBITDA 14.5
EPS(TTM)0.9
EY5.94%
EPS(NY)0.82
Fwd EY5.41%
FCF(TTM)1.62
FCFY10.66%
OCF(TTM)1.62
OCFY10.69%
SpS2.7
BVpS6.15
TBVpS1.23
PEG (NY)0.32
PEG (5Y)1.3
Graham Number11.16
Profitability
Industry RankSector Rank
ROA 11.77%
ROE 15.23%
ROCE 10.05%
ROIC 7.23%
ROICexc 7.75%
ROICexgc 33.36%
OM 25.51%
PM (TTM) 34.68%
GM 74.32%
FCFM 59.76%
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.45
Debt/EBITDA 0.67
Cap/Depr 1.2%
Cap/Sales 0.17%
Interest Coverage 250
Cash Conversion 152.24%
Profit Quality 172.34%
Current Ratio 1.3
Quick Ratio 0.98
Altman-Z 6.53
F-Score7
WACC8.56%
ROIC/WACC0.85
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y52.6%
EPS Next 2Y14.3%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year51.28%
Revenue Next 2Y24.88%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year144.15%
EBIT Next 3Y45.8%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%

CIPHER PHARMACEUTICALS INC / CPH.CA FAQ

What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.


What is the valuation status for CPH stock?

ChartMill assigns a valuation rating of 6 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.


What is the profitability of CPH stock?

CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.


What are the PE and PB ratios of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

The Price/Earnings (PE) ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 16.84 and the Price/Book (PB) ratio is 2.46.


How financially healthy is CIPHER PHARMACEUTICALS INC?

The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.